Research: Neuroendocrine Prostate Cancer Market Forecast to 2034
A new report analyzes the market and epidemiology of neuroendocrine prostate cancer (NEPC) through 2034. Treatment options are limited, highlighting an urgent need for new therapies.
ResearchAndMarkets.com has released a new report providing an in-depth analysis of the market and epidemiology of neuroendocrine prostate cancer (NEPC), with forecasts extending to 2034. The report underscores that NEPC is an aggressive form of prostate cancer with currently limited treatment options, emphasizing the urgent need for novel therapeutic approaches.
NEPC can arise either as a de novo form or as a resistance mechanism to hormonal therapies for conventional prostate adenocarcinoma. Both subtypes, de novo NEPC and treatment-emergent NEPC (T-NEPC), have demonstrated poor prognoses and low survival rates, with a five-year survival expectancy projected at just five years.
Current treatment strategies for NEPC often draw from approaches used for small cell lung cancer (SCLC), including platinum-based drugs and etoposide. The report highlights BXCL701, developed by BioXcel Therapeutics, as showing potential for treating SCNC. Several other emerging therapies, such as Peluntamig (Phanes Therapeutics) and tarlatamab (Amgen), are also under development.
The report covers market insights for the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. It analyzes current treatment practices, drug market shares, and future treatment trends, reflecting the growing significance of NEPC within cancer research.